Median PFS was 13.8 months (95% CI, 10.7–22.0) in patients with mutated EZH2 and 11.1 months (95% CI, 3.7–14.6) in those with wild-type EZH2. The most common grade ≥ 3 treatment-related AEs were thrombocytopenia (3%), neutropenia (3%), and anemia (2%) [53]. The gene discussed is EZH2; the disease is anemia.